

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001890004
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Ventyx Biosciences, Inc.
SEC File Number 001-40928
Address of Issuer 662 Encinitas Blvd, Suite 250
Encinitas
CALIFORNIA
92024
Phone (760) 593-4832
Name of Person for Whose Account the Securities are To Be Sold NSV Partners III LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer 10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave, 4th Fl New York NY 10022	500000	15105000.00	58710000	10/09/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	-----------------------------------	-----------------	---------------------	-------------------------------	-----------------	---------------------

Common	04/17/2019	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	61172	04/17/2019 N/A
Common	06/18/2019	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	79964	06/18/2019 N/A
Common	08/21/2019	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	68442	08/21/2019 N/A
Common	11/27/2019	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	37856	11/27/2019 N/A
Common	12/20/2019	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	93997	12/20/2019 N/A
Common	02/07/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	6965	02/07/2020 N/A
Common	04/28/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	50932	04/28/2020 N/A
Common	06/02/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	10795	06/02/2020 N/A
Common	07/01/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	36016	07/01/2020 N/A
Common	08/13/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	24317	08/13/2020 N/A
Common	08/28/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	2206	08/28/2020 N/A
Common	12/21/2020	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	927	12/21/2020 N/A
Common	01/13/2021	Pre IPO Investment	Ventyx Biosciences	<input type="checkbox"/>	26411	01/13/2021 N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
NEW PARTNERS III, LP 500 W. Putnam Ave, Suite 400 Greenwich CT 06830	Common	07/07/2023	100000	3523056.00
NEW PARTNERS III, LP 500 W. Putnam Ave, Suite 400 Greenwich CT 06830	Common	07/11/2023	28646	1075411.23
NEW PARTNERS III, LP 500 W. Putnam Ave, Suite 400 Greenwich CT 06830	Common	07/12/2023	3275	123219.35
NEW PARTNERS III, LP 500 W. Putnam Ave, Suite 400 Greenwich CT 06830	Common	07/28/2023	611	22932.64
NEW PARTNERS III, LP 500 W. Putnam Ave, Suite 400 Greenwich CT 06830	Common	07/31/2023	10803	406035.29
NEW PARTNERS III, LP 500 W. Putnam Ave, Suite 400 Greenwich CT 06830	Common	09/18/2023	56665	2142632.85

144: Remarks and Signature

Remarks All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 02/24/2023, and all representations regarding material non-public information were made as of the adoption of the plan.

Date of Notice 10/09/2023

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 02/24/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Thomas Lavin

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)